Glenmark launches Epinephrine injection : – Glenmark Pharmaceuticals on Thursday said it has launched the generic version of Epinephrine injection multiple-dose vial in the US, which is eligible for 180 days of competitive generic therapy (CGT) exclusivity. Glenmark Pharmaceuticals Inc, USA, an arm of the company,
The injection is used to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock and also for emergency treatment of allergic reactions.
“This launch of Epinephrine injection USP, 10 mg/10 mL (1 mg/mL) multiple-dose vial is eligible for 180 days of CGT exclusivity,” the company said.
Citing IQVIA sales data for the 12-month period ended December 2024, Glenmark said the Epinephrine injection 10 mg/10 mL (1 mg/mL) market achieved annual sales of approximately USD 42.7 million.
According to IQVIA, sales data for the 12-month period ending December 2024, the Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) market achieved annual sales of approximately $42.7 million.
Latest Technology news of the country and the world first on techbugs Follow us on Twitter and Join Google news, Our Youtube Channel for More
